{"id":"NCT00623194","sponsor":"Novo Nordisk A/S","briefTitle":"Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689","officialTitle":"A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 Years With Type 1 Diabetes on a Basal-Bolus Regimen With Insulin Aspart as Bolus Insulin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2008-02-25","resultsPosted":"2011-01-24","lastUpdate":"2016-11-28"},"enrollment":146,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"insulin detemir","otherNames":[]},{"type":"DRUG","name":"insulin aspart","otherNames":[]}],"arms":[{"label":"insulin detemir","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.","primaryOutcome":{"measure":"Insulin Detemir-insulin Aspart Cross-reacting Antibodies","timeFrame":"week 0, 52 and 104","effectByArm":[{"arm":"Insulin Detemir","deltaMin":31.11,"sd":1.25}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":32,"countries":["Bulgaria","Czechia","Denmark","Finland","France","Hungary","North Macedonia","Poland","Russia","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["27600385"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":146},"commonTop":["Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Pharyngitis","Influenza"]}}